JS016
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for JS016, covering 2021-10-21 to 2022-07-18. Get the full timeline:
Most recent: Clinical Trial Update: JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects [Phase 1, Phase 2]